It is worth mentioning that our series also includes 85 female carriers of a mutation in the MSH6 gene, 32 of whom (37.6%) developed gynecological cancer (24 EC, 5 OC and 3 synchronous EC and OC), all from the non-RRGS group (Table 4 and Table 5). This evidence concerns the gene MSH6 and female reproductive organ cancer.